Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

May 31, 2006

Conditions
Raynaud's Disease
Interventions
DRUG

Topical organogel with nitroglycerin

Trial Locations (19)

11733

SUNY Stony Brook, East Setauket

12206

The Center for Rheumatology, Albany

20007

Georgetown University Medical Center, Washington D.C.

21224

Johns Hopkins Bayview Medical Center, Baltimore

27710

Duke University, Durham

29425

Medical University of South Carolina, Charleston

43614

Medical University of Ohio, Toledo

49546

Arthritis Education & Treatment Center, PLLC, Grand Rapids

53226

Medical College of Wisconsin, Milwaukee

60637

University of Chicago Center for Advanced Medicine, Chicago

77030

University of Texas Medical School at Houston, Houston

80204

University of Colorado at Denver and Health Sciences Center, Denver

94305

Stanford Medical School, Stanford

98101

Virginia Mason Benaroya Research Institute, Seattle

06030

University of Connecticut, Farmington

02118

Boston University School of Medicine, Boston

08903

University of Medicine and Dentistry of New Jersey, New Brunswick

N6A 4V2

St. Joseph's Health Care, London

H3T 1E2

SMBD Jewish General Hospital, Montreal

Sponsors
All Listed Sponsors
lead

MediQuest Therapeutics

INDUSTRY